Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

BACKGROUND: Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without diabetes. Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist that is approved for treatment of T2D. METHODS: This meta-anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdinand, Keith C., Botros, Fady T., Atisso, Charles M., Sager, Philip T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765050/
https://www.ncbi.nlm.nih.gov/pubmed/26912057
http://dx.doi.org/10.1186/s12933-016-0355-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765050/
https://www.ncbi.nlm.nih.gov/pubmed/26912057
http://dx.doi.org/10.1186/s12933-016-0355-z

Ejemplares similares